Business · 02/09/2010Updated: 10/17/2026 · 1 min read
FDA Sets Regulatory Review Period for ONGLYZA Patent Extension
Summary
The US Food and Drug Administration has determined the regulatory review period for the patent extension of ONGLYZA, a medication developed by Eli Lilly and Company, to allow for the potential extension of its patent protection.
Original source language: Federal Register — Health and Human ServicesOpen original release →